Inhibikase Therapeutics Discusses New Platform for Infectious Disease
Pharmaceuticals at BIOCOM 2009
SAN DIEGO, Oct. 26 /PRNewswire/ -- Inhibikase Therapeutics, a specialty
pharmaceutical company based in Atlanta, Georgia, will discuss simultaneous
antiviral and antibacterial activity from small molecule agents at the 2009
BIOCOM Investor Conference. Employing a host-factor targeted approach,
Inhibikase will illustrate the utility of IkT-001 and IkT-041 to treat
multiple infectious diseases in humans.
The Company's flu program has identified a compound, IkT-041, comparable in
activity to viral neuraminidase inhibitors (e.g. Tamiflu, Relenza), but one
that is far less likely to stimulate resistance. IkT-041 has excellent human
dosing metrics (up to 3000 mg/day), outstanding safety history in humans and
an oral bioavailability > 70%.
The Company's orphan drug program is focused on satisfying an unmet medical
need for the treatment of polyomavirus infections. The human polyomaviruses,
JC and BK, are responsible for fatal disorders of the brain and kidney, to
include progressive multifocal leukoencephalopathy (PML), an AIDS-defining
disease that also afflicts patients on autoimmune disorder treatments for MS,
lupus and arthritis. IkT-001 has a mechanism of action that can suppress
polyomavirus reactivation in viral reservoirs, even in patients who are immune
compromised. In some cases, a therapeutic vaccine effect can be realized with
this product.
The Company is on track to file 3 Initial New Drug applications in 2010 or
early 2011 and enter late stage clinical trials shortly thereafter. First
product launch is slated for 2013, addressing a total market of greater than
100 million patients with annual revenue potential of at least $2.3 billion.
SOURCE Inhibikase Therapeutics
Milton H. Werner, PhD, President & CEO of Inhibikase Therapeutics, mobile,
+1-917-494-0831, mhwerner@gmail.com
